Previous Close | 1.6100 |
Open | 1.6100 |
Bid | 1.6300 x 1100 |
Ask | 1.6600 x 1000 |
Day's Range | 1.6100 - 1.6784 |
52 Week Range | 1.4100 - 3.5200 |
Volume | |
Avg. Volume | 319,105 |
Market Cap | 38.413M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
U.S.-listed shares of Evaxion Biotech A/S jumped about 17% in premarket trading on Tuesday after the company said the Food and Drug Administration has allowed a Phase 2b clinical trial testing its experimental cancer vaccine to move forward. The study is evaluating Evaxion's EVX-01 in combination with Merck & Co. Inc.'s Keytruda as a treatment for metastatic melanoma in Australia, Europe, and the U.S. Erik Heegaard, Evaxion's chief medical officer, said the FDA's decision "is an important step t
Evaxion Biotech A/S (NASDAQ: EVAX) has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB for the joint development of a novel cytomegalovirus (CMV) vaccine candidate. During the discovery phase of the collaboration, Evaxion will use its proprietary AI platform, RAVEN, to design a next-generation vaccine candidate that elicits both cellular and humoral/antibody responses. The antigen constructs derived from Evaxion's AI platform will be produced by ExpreS2ion,
Evaxion Biotech A/S (NASDAQ: EVAX) has announced interim safety and immunogenicity data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02. In the clinical study, EVX-02 is given in combination with a checkpoint inhibitor and targets cancer mutations, neoantigens, in patients with resected melanoma. "We are thrilled to announce promising interim data from the first eight patients...All patients demonstrated a specific T-cell immune response induced by the trea